Eli Lilly Partners With Hims & Hers to Expand GLP-1 Access
Article excerpt
Highlighted: the sentence this signal was extracted from
An important element of the agreement is the commitment to maintaining independent clinical decision-making. Providers operating through Hims & Hers will continue to determine which treatment is appropriate for each individual, rather than prescribing medicines based on the commercial arrangement. This distinction is significant in a market where demand for obesity medicines has created increased attention around the availability, sourcing and regulation of treatments. Providing access to Lilly's FDA-approved products through the platform establishes a direct relationship between the pharmaceutical manufacturer and the digital healthcare provider. NVIDIA CEO: Jensen Huang | HQ: Santa Clara, California NVIDIA is a US technology company specialising in accelerated computing and artificial intelligence. Eli Lilly and NVIDIA are investing up to US$1bn over five years in an AI co-innovation lab focused on drug discovery, robotics and physical AI. Insilico Medicine CEO: Alex Zhavoronkov | HQ: Hong Kong Insilico Medicine is an AI-powered drug discovery company. Eli Lilly expanded its partnership with Insilico in 2026 through a deal worth up to US$2.75bn, combining Insilico's AI platforms with Eli Lilly's drug development expertise to advance novel oral medicines. CVS Health CEO: David Joyner | HQ: Woonsocket, Rhode Island Eli Lilly is partnering with CVS to expand access to...
Keep reading with a free account
The rest of this article, and every signal for Eli Lilly, is in your free account.
